Shanghai Aladdin Biochemical Technology (SH:688179) Western Securities·2025-11-27 01:20Group 1: Gushengtang (2273.HK) Overview - Gushengtang is accelerating its overseas expansion and increasing share buybacks, with projected revenues of 34.31, 43.14, and 51.80 billion CNY for 2025-2027, representing year-on-year growth of 13.52%, 25.75%, and 20.07% respectively [3][5] - The company plans to acquire 100% of Dazhongtang PTE. LTD., enhancing its presence in Singapore's traditional Chinese medicine market and adding 14 new clinics [3][4] - The share buyback program, totaling up to 600 million HKD, reflects the company's confidence in its long-term business prospects and aims to enhance shareholder value [4][5] Group 2: Aladdin (688179.SH) Overview - Aladdin is expanding its product matrix through the acquisition of 35% of Youke Instrument for 61.25 million CNY, which specializes in laboratory analysis instruments [6][8] - The acquisition is expected to enhance Aladdin's product offerings and customer engagement, leveraging its existing resources and channels [6][7] - Aladdin has completed six investment projects since 2023, diversifying its product lines in various fields, including recombinant proteins and biochemical reagents [7]